| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 6.31 | 12.6% | 37.7% |
| Total Income | 6.31 | 12.6% | 37.7% |
| Expenditure | 77.93 | 9.2% | 10.9% |
| PBT | -67.20 | 8.9% | 18.5% |
| Net Profit | -67.26 | 9.4% | 28.3% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.52 | 51.4% | 73.2% |
Generate Biomedicines Reports Q2 2026 Financial Results and Business Update
06 Aug 2026 · 6 Aug, 3:42 pm
Summary
Generate Biomedicines reported second quarter 2026 revenue of $6.3 million, a decrease from $10.1 million in the prior year quarter. The company's net loss widened to $67.3 million from $56.7 million in the same period last year, driven by increased research and development expenses. Despite the revenue decline, the company highlighted significant progress in its clinical pipeline, including advancements in Phase 3 studies for GB-0895 and enrollment completion for the first cohort of the GB-4362 Phase 1 study. Management emphasized the team's focus on execution and the platform's ability to advance multiple programs simultaneously.
Key Highlights
- 1
Generate Biomedicines reported $6.3 million in revenue for the second quarter ended June 30, 2026, compared to $10.1 million for the same period in 2025.
- 2
The company had approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
- 3
Net loss for the quarter ended June 30, 2026, was $67.3 million, compared to $56.7 million for the same period in 2025.
- 4
Research and development expenses increased to $64.3 million for the quarter ended June 30, 2026, from $59.7 million in the prior year period.
- 5
General and administrative expenses rose to $13.6 million for the quarter ended June 30, 2026, from $10.5 million in the prior year period.
- 6
The SOLAIRIA-1 and SOLAIRIA-2 Phase 3 studies for GB-0895 in severe asthma continue to advance with recruitment underway across all six global regions.
- 7
All patients were enrolled in the first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer).
Management Comments
Mike Nally
Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicines drove strong progress in the second quarter. With GB-0895, our global Phase 3 SOLAIRIA studies in severe asthma continue to advance. We dosed the first cohort in our Phase 1 study of our MMAE neutralizer, designed to reduce treatment-limiting toxicities from antibody drug conjugates, and Novartis advanced a biologic designed with our platform into its preclinical pipeline for further development. Together, these milestones demonstrate that we can repeatedly advance programs in our own pipeline and through collaborations.
Jason Silvers
Our platform and continued pipeline progress create optionality. Because our platform is inherently scalable, we can simultaneously advance our internal pipeline, execute on existing collaborations, and enter into additional strategic partnerships. That growing opportunity set makes disciplined capital allocation increasingly important as we determine the optimal path for each program and opportunity.
Informational and educational content only. Not investment advice.